

Sclerotherapy and Prolotherapy for Joints and Tendons

Table of Content
Purpose
Description & Definitions
Criteria
Coding
Document History
References
Special Notes
Keywords

<u>Effective Date</u>	9/2007
<u>Next Review Date</u>	8/15/2024
<u>Coverage Policy</u>	Medical 108
<u>Version</u>	6

Member-specific benefits take precedence over medical policy and benefits may vary across plans. Refer to the individual’s benefit plan for details [*](#).

Purpose:

This policy addresses the medical necessity of prolotherapy and sclerotherapy.

Description & Definitions:

Prolotherapy is injections into a site on the body to relieve pain.

Joint sclerotherapy is injecting a substance into a joint to produce an irritation to promote healing.

Reconstructive Ligament Therapy with Injections of Sclerosing Agents are injections into a site on the body to relieve pain.

Criteria:

Prolotherapy, joint sclerotherapy and reconstructive ligament therapy are considered **not medically necessary** for any indication.

Coding:

Medically necessary with criteria:

Coding	Description
	None

Considered Not Medically Necessary:

Coding	Description
M0076	Prolotherapy

U.S. Food and Drug Administration (FDA) - approved only products only.

Document History:

Revised Dates:

- 2021: February
- 2020: January
- 2015: March
- 2013: August
- 2012: August
- 2011: September
- 2010: December
- 2009: November

Reviewed Dates:

- 2023: August
- 2022: August
- 2020: November
- 2019: November
- 2018: October
- 2017: November
- 2016: July
- 2015: August
- 2014: August
- 2010: August, November
- 2009: August
- 2008: August

Effective Date:

- September 2007

References:

Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2023). Retrieved July 13, 2023, from MCG 26th Edition: <https://careweb.careguidelines.com/ed26/index.html>

A Comprehensive Update of Prolotherapy in the Management of Osteoarthritis of the Knee. (2022, May 31). Retrieved July 13, 2023, from Orthopedic Reviews: <https://orthopedicreviews.openmedicalpublishing.org/article/33921-a-comprehensive-update-of-prolotherapy-in-the-management-of-osteoarthritis-of-the-knee>

Interventional Pain Management. (2023-04-09). Retrieved July 13, 2023, from Carelon Medical Benefits Management: <https://guidelines.carelonmedicalbenefitsmanagement.com/interventional-pain-management-2023-04-09/?highlight=Prolotherapy&hilite=Prolotherapy>

Local Coverage Determination (LCD) Trigger Point Injections L37635. (2020, Nov). Retrieved July 13, 2023, from Centers for Medicare and Medicaid Services LCD: <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37635&ver=13&keyword=Prolotherapy&keywordType=starts&areald=all&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=1>

National Coverage Determination (NCD) Prolotherapy, Joint Sclerotherapy, and Ligamentous Injections with Sclerosing Agents (150.7). (1999). Retrieved July 13, 2023, from Centers for Medicare & Medicaid Services NCD: <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=15&ncdver=1&keyword=Prolotherapy&keywordType=starts&areald=all&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=1>

Overview of the management of overuse (persistent) tendinopathy. (2021, June). Retrieved July 13, 2023, from UpToDate: <https://www.uptodate.com/contents/overview-of-the-management-of-overuse-persistent->

[tendinopathy?search=Prolotherapy%20&source=search_result&selectedTitle=2~13&usage_type=default&display_rank=2#](#)

Procedure Fee Files & CPT Codes. (2023). Retrieved July 13, 2023, from Department of Medical Assistance Services: <https://www.dmas.virginia.gov/for-providers/rates-and-rate-setting/procedure-fee-files-cpt-codes/> & <https://www.dmas.virginia.gov/for-providers/cardinal-care-transition/>

Prolotherapy. (2023, Mar 31). Retrieved July 13, 2023, from Cigna - EviCore: https://www.evicore.com/-/media/files/evicore/provider/network-standard/cigna-cmm-204-prolotherapy_v102023_final_pub02202023.pdf

Prolotherapy for Osteoarthritis. (2023). Retrieved July 13, 2023, from Arthritis Foundation: <https://www.arthritis.org/diseases/more-about/prolotherapy-for-osteoarthritis>

Prolotherapy For Treatment Of Joint And Ligamentous Conditions - ARCHIVED Sep 8, 2013. (n.d.). Retrieved July 13, 2023, from Hayes: <https://evidence.hayesinc.com/report/dir.scle0003>

Special Notes: *

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving, and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

Services mean both medical and behavioral health (mental health) services and supplies unless We specifically tell You otherwise. We do not cover any services that are not listed in the Covered Services section unless required to be covered under state or federal laws and regulations. We do not cover any services that are not Medically Necessary. We sometimes give examples of specific services that are not covered but that does not mean that other similar services are covered. Some services are covered only if We authorize them. When We say You or Your We mean You and any of Your family members covered under the Plan. Call Member Services if You have questions.

Keywords:

SHP Prolotherapy, SHP Medical 108, injections, pain relief, non-surgical ligament reconstruction, tendon reconstruction, joint pain